TY  - JOUR
PY  - 2019//
TI  - Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients
JO  - Journal of critical care
A1  - Lorente, Leonardo
A1  - Martín, María M.
A1  - Ramos, Luis
A1  - Argueso, Mónica
A1  - Cáceres, Juan J.
A1  - Solé-Violán, Jordi
A1  - Jiménez, Alejandro
A1  - Borreguero-León, Juan M.
A1  - González-Rivero, Agustín F.
A1  - Orbe, Josune
A1  - Rodriguez, Jose A.
A1  - Páramo, José A.
SP  - 117
EP  - 121
VL  - 51
IS  - 
N2  - PURPOSE: Previously, higher circulating levels of matrix metalloproteinase (MMP)-9 and tissue inhibitor matrix metalloproteinases (TIMP)-1 were reported in the first hours after TBI in blood samples from patients with poor prognosis. Thus, the objectives of this study were to determine whether MMP-9 and TIMP-1 levels during the first week of a severe TBI could be used as biomarker predictive of mortality. <br><br>METHODS: We included patients with severe TBI (defined as Glasgow Coma Scale lower than 9), and with Injury Severity Score in non-cranial aspects lower than 9. We determined serum concentrations of MMP-9 and TIMP-1 at days 1, 4 and 8 of TBI. <br><br>RESULTS: TIMP-1 concentrations at days 1 (p < .001), 4 (p = .001), and 8 (p = .01) of TBI were higher in non-surviving (n = 34) than in surviving (n = 90) patients. ROC curve analyses showed an area under curve of TIMP-1 concentrations at days 1, 4, and 8 of TBI to predict 30-day mortality of 78% (p < .001), 76% (p < .001) and 71% (p = .02) respectively. <br><br>CONCLUSIONS: The most relevant new findings of our study were that TIMP-1 levels during the first week of a severe TBI were higher in non-surviving than in surviving patients and that could be used as biomarker predictive of mortality.<br><br>Copyright © 2019 Elsevier Inc. All rights reserved.<p />  <p>Language: en</p>
LA  - en
SN  - 0883-9441
UR  - http://dx.doi.org/10.1016/j.jcrc.2019.02.014
ID  - ref1
ER  -